Story

Amgen Reports Positive Results for Cholesterol Drug

Amgen Inc. said Monday it had received positive results from clinical tests of an experimental heart medication that it hopes will be one of its next blockbuster drugs.

Story

Amgen Gains on Drug Study

Amgen Inc. announced on Monday positive human trial results for a cancer drug that was the focus of a multibillion dollar acquisition last year.

Story

Changing With The Times

Sun Valley Foods is thriving after than 85 years in business

Story

Model Firm

Drug Makersโ€™ Adoption of Software Boosts Simulations Plus.

Simulations Plus, a Lancaster modeling and simulation software firm, is soaring both in terms of revenue and income. Its stock price is up over 100 percent in the last year.

Tease photo
Story

Study Could Boost Medtronic Insulin Pump Sales

Medical Devices: Better blood-sugar control found among Type 2 pump users.

A new study shows that Medtronic Inc. insulin pumps achieve better blood sugar control than multiple daily insulin injections for Type 2 diabetics โ€“ a conclusion that should help the device gain further market penetration.

Story

Rent the Runway Opens โ€˜Dream Closetโ€™ in Valley

APPAREL: Customers can access new clothes daily on subscription basis.

Online luxury apparel rental service Rent the Runway opened its flagship West Coast location on Oct. 21 in Woodland Hills.

Story

Lancaster Add

Origins: First settled by M.L. Wicks, a farmer, the area was initially known for its alfalfa and gold-mining. Later, poultry farms were opened in the region.

Story

Boosting Technology

Installation of cutting edge equipment accompanies facilities' expansion

Story

Farmers Appoints HR Chief

Farmers Insurance Group, based in Woodland Hills, has named Suzie Elliott its new head of human resources.

Story

Congressman to Amgen: Stop Advertising Anemia Drug

A congressman has asked Thousand Oaks drug maker Amgen Inc. to stop advertising its popular anemia drugs until a federal investigation into its safety is completed.

Story

Kythera Chief Rings Nasdaq Bell

Keith Leonard, the chief executive of Kythera Biopharmaceuticals Inc., rang the Nasdaq opening bell Wednesday in New York, as the company announced positive results from clinical trials of its leading drug candidate.

Story

Brazilian Sales Boost Outlook at MannKind

BIOTECH: Revenues from Afrezza jump 46 percent year-over-year.

MannKind Corp. achieved noteworthy progress for international sales of its inhalable insulin Afrezza

Story

Amgen Pleads Guilty, Pays $762 Million in Penalties

Amgen Inc. will pay $762 million after it accepted criminal liability on Tuesday to illegally marketing its anemia drug Aranesp.

Story

MannKind Insulin Drug Approval Gets Further Delay

The U.S. Food & Drug Administration has delayed its approval decision for MannKind Corp.โ€™s application for its new diabetes drug due to further questions about clinical data,

Story

MannKind Shares Rise on New Studies

Shares of MannKind Corp. (MNKD) jumped nearly 17 percent on Monday, following positive data presented at an American Diabetes Association event about the companyโ€™s flagship product, Afrezza.

Story

City, County Officials Seek Answers About Aliso Canyon

Los Angeles City and county officials have submitted motions endorsing a state legislative bill to prohibit gas injection at Aliso Canyon until the last yearโ€™s leak is explained.

Story

Knees Are Not Meant For Knocking

USC starts clinical trial to study stem cell treatment on joints.

Innovation: A stem cell study in the Antelope Valley could lead to new therapies for knee pain.

Story

MannKind Stock Soars on Afrezza Label Update

BIOTECH: Shares gain 152 percent on perception that sales will likely rise.

Can MannKind maintain its recent stock price surge?

Story

CORPORATE FOCUS---MiniMed Inc.

You would think a company that has grown its revenues 273 percent since going public in 1995 would be ready for a breather, but not MiniMed Inc.

Story

MannKind Signs Cancer Licensing Deal

MannKind Corp. announced on Tuesday that it has signed a licensing deal worth some $140 million that allows a San Jose company to take over development and production of a novel cancer treatment.